Pamidronate - A promising new candidate for the management of spondyloarthropathy

Indian Journal of Medical Sciences

Volumn 59, Issue 4, 2005, Pages 165-170

  Akerkar, S M ^a   Bichile, L S ^a  

^a KEM HOSPITAL   (India)

Author keywords

Ankylosing spondylitis; Bisphosphonates; Pamidronate; Spondyloarthropathy

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID; PLACEBO;

ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; ARTICLE; CHEMICAL STRUCTURE; CLINICAL TRIAL; DISEASE DURATION; DRUG EFFECT; DRUG FEVER; FLU LIKE SYNDROME; HISTORY OF MEDICINE; HUMAN; HYPOCALCEMIA; MYALGIA; NONHUMAN; SPONDYLOARTHROPATHY;

EID: 18644371899     PISSN: 00195359     EISSN: None     Source Type: Journal    
DOI: 10.4103/0019-5359.16124     Document Type: Article

References (27)

1. Menschutkin N. Ueber die Einwirkung des Chlorazetyls auf phosphorige Säure. Ann Chem Pharm 1865;133:317-20.
2. Blomen LJMJ. History of the bisphosphonates: discovery and history of the non-medical uses of bisphosphonates. In:Bijvoet OLM, Fleisch HA, Canfield RE, Russell RGG, editors. Bisphosponate on bones. Amsterdam: Elsevier; 1995. p. 111-24.
3. Fleisch H, Russell RGG, Francis MD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science (Wash, DC) 1969;165:1262-4.
4. Francis MD, Russell RGG, Fleisch H. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science (Wash, DC) 1969;165:1264-6.
5. Fleisch H, Russell RGG, Straumann F. Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature 1966;212:901-3.
6. Dunn CJ, Galinet LA, Wu H, Nugent RA, Schlachter ST, Staite ND, et al. Demonstration of novel anti-arthritic and anti-inflammatory effects of diphosphonates. J Pharmacol Exp Ther 1993;266:1691-8.
7. Nugent RA, Schlachter ST, Murphy M, Dunn CJ, Staite ND, Galinet LA, et al. Carbonyl-containing bisphosphonate esters as novel anti-inflammatory and antiarthritic agents. J Med Chem 1994;37:4449-54.
8. Schlachter ST, Galinet LA, Shields SK, Aspar DG, Dunn CJ, Staite ND, et al. Anti-inflammatory/antiarthritic ketonic bisphosphonic acid esters. Bioorg Med Chem Lett 1998;8:1093-6.
9. Nugent RA, Murphy M, Schlachter ST, Dunn CJ, Smith RJ, Staite ND, et al. Pyrazoline bisphosphonate esters as novel anti-inflammatory and antiarthritic agents. J Med Chem 1993;36:134-9.
10. Van Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 1999;264:108-11.
11. Khwaja A, Conolly J, Hendry B. Prenylation inhibitors in renal disease. Lancet 2000;355:741-4.
12. Cecchini MG, Fleisch H. Bisphosphonates in vitro specifically inhibit, among the hematopoietic series, the development of the mouse mononuclear phagocyte lineage. J Bone Miner Res 1990;5:1019-27.
13. Stevenson PH, Stevenson JR. Cytotoxic and migration inhibitory effects of bisphosphonates on macrophages. Calcif Tissue Int 1986;38:227-33.
14. Pennanen N, Lapinjoki S, Urti A, Monkkonen J. Effect of liposomal and free bisphosphonates on the IL-10, IL-6 and TNF alpha secretion from RAW 264 cells in vitro. Pharm Res 1995;12:916-22.
15. Sato M, Graser W. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J Bone Miner Res 1990;5:31-40.
16. Sansoni P, Passeri G, Fagnoni F, Mohagheghpour N, Snelli G, Brianti V, et al. Inhibition of antigen-presenting cell function by alendronate in vitro. J Bone Miner Res 1995;10:1719-25.
17. Redlich K, Hayer S, Maier A, et al. Tumor necrosis factor a-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 2002;46:785-92.
18. Luckman SP, Hughes DE, Coxon FP, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998;13:581-9.
19. Francis MD, Hovancik K, Boyce RW. NE-58095: a diphosphonate which prevents bone erosion and preserves joint architecture in experimental arthritis. Int J Tissue React 1989;11:239-52.
20. Flora L. Comparative antiinflammatory and bone protective effects of two diphosphonates in adjuvant arthritis. Arthritis Rheum 1979;22:340-6.
21. Maksymowych WP, Jhangri GS, Leclercq S, Skeith K, Yan A, Russell AS. An open study of pamidronate in the treatment of refractory ankylosing spondylitis. J Rheumatol 1998;25:714-7.
22. Maksymowych WP, Lambert R, Jhangri GS, Leclercq S, Chiu P, Wong B, et al. Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy. J Rheumatol 2001;28:144-55.
23. Maksymowych WP, Jhangri GS, Fitzgerald AA. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 2002;46:766-73.
24. Haibel H, Brandt J, Rudwaleit M, Soerensen H, Sieper J, Braun J. Treatment of active ankylosing spondylitis with pamidronate. Rheumatology 2003;42:1018-20.
25. Cairns AP, Wright SA, Taggart AJ, et al. An open study of pulse pamidronate treatment in severe ankylosing spondylitis, and its effect on biochemical markers of bone turnover. Ann Rheum Dis 2005;64:338-9.
26. Buckler HM, Mercer SJ, Davison CE, et al. Evaluation of adverse experiences related to pamidronate infusion in Paget's disease of bone. Ann Rheum Dis 1998;57:572.
27. Singh R, Menon Y, Cuchacovich R, et al. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis: comment on the article by Maksymowych et al. Arthritis Rheum 2003;48:583-4.